Ann: Board Changes, page-12

Pogues, I would say the sp is a barometer of sucess, and a really important on (esp. for shareholders!), but not the barometer of sucess as a CEO.

Sure, the spray business had some potential, but the difficulty of reformulating a generic into a spray compound masked the fact this was ultimately a low margin business that needed volume and multiple products in market. Low margin, middling volume is fine for a private company, but would never satisfy public investors.

Global industries are shifting around cellular therapies. Hopper and Baker have bought ALA a chip and a chair at a very large and lucrative table. ALA is not the only outfit playing this game, and they are well behind the curve compared to many competitors. But their prospects for creating shareholder value have increased enrmously

This 'transformation', and bringing quality directors like Liz and Deb to the board, is, imho, a better barometer of success for the CEO.